Ab­bisko signs $70M up­front deal with Mer­ck KGaA for PhI­II can­cer drug

Shang­hai-based Ab­bisko Ther­a­peu­tics has lined up an­oth­er part­ner for its on­col­o­gy pipeline and will re­ceive $70 mil­lion up­front as Mer­ck KGaA grabs com­mer­cial­iza­tion rights to the biotech’s lead as­set in Chi­na.

Mer­ck KGaA will dish out up to $605.5 mil­lion to­tal, plus dou­ble-dig­it per­cent­age roy­al­ties on po­ten­tial fu­ture net sales, to nab com­mer­cial­iza­tion rights to Ab­bisko’s oral small mol­e­cule pim­i­co­tinib, which is be­ing stud­ied in a glob­al Phase III for pa­tients with tenosyn­ovial gi­ant cell tu­mor, or TGCT.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER